clock menu more-arrow no yes

Filed under:

The other good COVID-19 vaccine news from today

Novavax Inc. will receive ‘fast track’ status toward its release.

This May 4, 2020, file photo provided by the University of Maryland School of Medicine, shows the first patient enrolled in Pfizer’s COVID-19 coronavirus vaccine clinical trial at the University of Maryland School of Medicine in Baltimore
This May 4, 2020, file photo provided by the University of Maryland School of Medicine, shows the first patient enrolled in Pfizer’s COVID-19 coronavirus vaccine clinical trial at the University of Maryland School of Medicine in Baltimore.
Associated Press

Novavax Inc. said Monday it will begin its delayed late-stage study for its coronavirus vaccine, and it may be put on the fast track, Reuters reports.

What’s going on?

Novavax said its vaccine — titled NVX-CoV2373 — received “fast-track” status from the Food and Drug Administration.

  • The expected data could receive approval and authorization from the FDA for distribution if the company finishes its trial, according to Reuters.
  • Novavax halted the trial back in September for about a month.

Key quote:

“While the regulatory review of this clinical program will be expedited, Novavax remains committed to a data-driven and scientifically rigorous approach in demonstrating safety and efficacy, which we believe will support confidence in the vaccine in the U.S. and globally,” Gregory M. Glenn, president of R&D at Novavax, said in a statement, according to MarketWatch.

What’s next?

Novavax said it will likely begin its Phase 3 clinical trial by the end of November.

  • “Depending on the overall COVID-19 attack rate, interim data in the UK trial, which is also event-driven, are expected as soon as early first quarter 2021,” according to Yahoo! Finance.